Ching-Hon Pui Selected Research

rasburicase (Elitek)

1/2019	Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies.
6/2008	Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.
1/2005	Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
3/2003	Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
4/2002	Rasburicase: a potent uricolytic agent.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ching-Hon Pui Research Topics

Disease

199	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2022 - 01/2002
79	Leukemia 07/2022 - 04/2002
67	Neoplasms (Cancer) 01/2022 - 04/2002
36	Residual Neoplasm 01/2022 - 06/2002
25	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 10/2002
18	Infections 10/2022 - 09/2003
16	Osteonecrosis (Kienbock's Disease) 01/2021 - 10/2004
13	Hypersensitivity (Allergy) 07/2022 - 09/2005
11	Philadelphia Chromosome 01/2021 - 01/2009
8	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 02/2009
7	Pain (Aches) 01/2022 - 03/2008
7	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 04/2010
7	Leukoencephalopathies 10/2016 - 12/2004
6	Overweight 01/2021 - 12/2006
6	Thrombosis (Thrombus) 01/2020 - 08/2003
6	Febrile Neutropenia 01/2020 - 04/2008
6	Genetic Predisposition to Disease (Genetic Predisposition) 11/2019 - 01/2006
6	Second Primary Neoplasms (Neoplasms, Second) 10/2019 - 07/2002
5	Obesity 01/2021 - 12/2002
5	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 02/2015
4	Neuralgia (Stump Neuralgia) 01/2022 - 12/2011
4	Brain Neoplasms (Brain Tumor) 01/2021 - 02/2005
4	Hypothyroidism 12/2019 - 04/2006
4	Seizures (Absence Seizure) 12/2019 - 08/2003
4	Hodgkin Disease (Hodgkin's Disease) 01/2018 - 03/2006
4	Neutropenia 03/2011 - 01/2004
3	Pancreatitis 01/2021 - 12/2009
3	Chronic Disease (Chronic Diseases) 10/2019 - 07/2009
3	Hypogonadism (Hypergonadotropic Hypogonadism) 06/2019 - 07/2007
3	Sepsis (Septicemia) 01/2019 - 09/2003
3	Glucosephosphate Dehydrogenase Deficiency 01/2019 - 04/2002
3	Central Nervous System Diseases (CNS Diseases) 11/2018 - 01/2006
3	Hyperglycemia 01/2017 - 12/2002
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2016 - 11/2002
3	Acute Kidney Injury (Acute Renal Failure) 12/2016 - 09/2012
3	Hyperuricemia 01/2010 - 03/2003

Drug/Important Bio-Agent (IBA)

38	Methotrexate (Mexate)FDA LinkGeneric 01/2021 - 07/2002
26	Asparaginase (Elspar)FDA Link 01/2022 - 12/2002
20	Pharmaceutical PreparationsIBA 01/2022 - 06/2002
17	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 11/2004
16	GlucocorticoidsIBA 01/2021 - 12/2002
15	Biological ProductsIBA 10/2020 - 08/2007
13	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 02/2002
12	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 01/2022 - 01/2002
10	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2004
10	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2009
9	Cytarabine (Cytosar-U)FDA LinkGeneric 12/2019 - 10/2002
8	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 04/2002
7	AntibodiesIBA 07/2022 - 01/2011
7	Growth Hormone (Somatotropin)IBA 01/2021 - 07/2002
7	NucleotidesIBA 01/2021 - 06/2003
6	pegaspargase (Oncaspar)FDA Link 07/2022 - 10/2019
6	Messenger RNA (mRNA)IBA 07/2022 - 08/2006
6	Proteins (Proteins, Gene)FDA Link 06/2021 - 01/2005
6	EnzymesIBA 01/2021 - 03/2003
6	Thioguanine (Tioguanine)FDA Link 01/2021 - 06/2003
6	Indicators and Reagents (Reagents)IBA 04/2015 - 06/2002
5	ChromatinIBA 01/2022 - 11/2019
5	RNA (Ribonucleic Acid)IBA 01/2022 - 04/2015
5	Dasatinib (BMS 354825)FDA Link 01/2022 - 01/2020
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 01/2012
5	Clofarabine (Clolar)FDA Link 01/2021 - 08/2011
5	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 09/2003
5	2-mercaptopurineIBA 01/2020 - 01/2002
5	AntimetabolitesIBA 01/2020 - 11/2004
5	Prednisone (Sone)FDA LinkGeneric 01/2019 - 01/2004
5	rasburicase (Elitek)FDA Link 01/2019 - 04/2002
4	Opioid Analgesics (Opioids)IBA 01/2022 - 12/2011
4	AntigensIBA 01/2021 - 06/2011
4	Folic Acid (Vitamin M)FDA LinkGeneric 12/2020 - 10/2004
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2006
4	SteroidsIBA 01/2016 - 12/2002
4	gamma-Glutamyl Hydrolase (Carboxypeptidase G2)IBA 05/2014 - 07/2002
3	Gabapentin (Neurontin)FDA LinkGeneric 01/2022 - 12/2011
3	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 08/2011
3	Transcription Factors (Transcription Factor)IBA 11/2021 - 09/2014
3	venetoclaxIBA 01/2021 - 01/2020
3	Prednisolone (Predate)FDA LinkGeneric 01/2020 - 08/2004
3	Alkylating AgentsIBA 12/2019 - 10/2014
3	Daunorubicin (Cerubidine)FDA LinkGeneric 10/2019 - 08/2004
3	Phosphotransferases (Kinase)IBA 01/2018 - 08/2012
3	purineIBA 01/2016 - 09/2004
3	Dihydrotachysterol (AT 10)IBA 12/2013 - 07/2007
3	Urate Oxidase (Uricase)IBA 01/2010 - 03/2003
3	Cladribine FDA LinkGeneric 01/2010 - 10/2002

Therapy/Procedure

134	Therapeutics 10/2022 - 02/2002
71	Drug Therapy (Chemotherapy) 01/2022 - 07/2002
26	Remission Induction 01/2022 - 07/2002
18	Radiotherapy 01/2020 - 08/2003
13	Cranial Irradiation 01/2021 - 01/2004
10	Aftercare (After-Treatment) 10/2022 - 08/2004
9	Hematopoietic Stem Cell Transplantation 01/2018 - 10/2003
6	Cell Transplantation 01/2019 - 02/2006
4	Induction Chemotherapy 01/2021 - 03/2011
4	Anesthesia 01/2020 - 11/2007
4	Transplantation 07/2013 - 02/2010
3	Central Venous Catheters 09/2022 - 07/2009
3	Antibiotic Prophylaxis 01/2021 - 07/2008
3	Immunotherapy 01/2020 - 01/2019
3	Combination Drug Therapy (Combination Chemotherapy) 07/2013 - 04/2005